

ANTEO SIGNS ASSAY DEVELOPMENT COLLABORATION WITH LUMOS DIAGNOSTICS

ASX Release

17 June 2019

Anteo Diagnostics Limited (ASX: ADO) ("**Anteo** or the **Company**") is pleased to report that it has signed a Collaboration Agreement with California based Point-of-Care (POC) company Lumos Diagnostics (**Lumos**), a spin out of medical technology firm Planet Innovation, and a recognised market leader in lateral flow assay development and reader design.

Anteo's Life Sciences division and Lumos will combine their expertise and technology in the development of a high sensitivity, lateral flow tests for the detection of very low concentrations of clinically important biomarkers.

Anteo has previously collaborated with Lumos on a Medical Counter Measures project led by the Defense Materials Technology Centre (DMTC) and Planet Innovation. This successful project won a National Innovation Award at the 2018 International Land Forces Exposition for its development of a field-deployable, handheld diagnostic device.

This new project has the potential to strengthen the collaborative relationship between the two parties and provide additional opportunities to more deeply assess the performance advantages that AnteoBind™ can deliver in the commercial development of lateral flow assays.

Specifically, this latest collaboration will focus on the development of a POC assay to detect a novel biomarker¹, at such a low concentration that it has not previously been able to be detected in a conventional POC Lateral Flow setting.

A successful outcome will demonstrate not only the well-established and superior performance of Lumos's assay design and reader technology, but also the major role AnteoBind™ plays in enhancing development of the materials required to build the latest generation of ultra-high sensitive Lateral Flow POC tests.

Lumos's Chief Technology Officer Sacha Dopheide said: *"We are pleased to have this opportunity to collaborate again with a familiar and trusted partner on this challenging lateral flow test development. We look forward to working with Anteo on this project."*

Anteo's Executive Director Christopher Parker added: *"Lumos Diagnostics is a world leader in lateral flow assay development, and this is a noteworthy collaboration on what is an important new customer project. We look forward to showcasing the advantages AnteoBind™ can bring to the Lumos assay development process and to reporting on the progress of this exciting collaboration in the very near future."*

Anteo's Life Sciences division now has over 20 collaborations underway which are at various stages of development, from early-stage feasibility testing to products that are near to realising commercial sales. Further updates on progress with this, and other Life Science collaborations are will occur in the coming 3-4 months.

¹A biomarker is a naturally occurring molecule, gene, or characteristic by which a particular pathological or physiological process, disease, etc. can be identified.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo Group is a Surface Chemical Company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Anteo’s customers operate in the life sciences, diagnostics, energy and medical devices markets.

ABOUT LUMOS GROUP – Lumos Diagnostics

Lumos Diagnostics provides rapid, cost effective, and complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to help healthcare professionals more accurately diagnose and manage diseases and medical conditions. Lumos provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures, and commercialises a suite of Lumos-branded POC tests (e.g. FebriDx). For more information on Lumos Diagnostics, visit lumosdiagnostics.com

For more information, please contact:

Harley Frankfurt, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow Anteo Diagnostics on Twitter:



<https://twitter.com/AnteoDX> or visit www.anteotech.com